New drug ME3241 enters first human safety tests

NCT ID NCT07422207

Recruiting now Knowledge-focused Sponsor: Meiji Pharma USA Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug called ME3241 in 104 healthy adults to see if it is safe and how the body handles it. Participants will receive either the drug or a placebo by infusion, and researchers will monitor for side effects and measure drug levels in the blood. The study is not looking for a treatment effect, but rather gathering essential safety data before any future disease-focused trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ME3241
What could go wrong: This is a very early phase 1 trial in healthy volunteers, so it is not designed to test if ME3241 works for any disease. The drug may prove unsafe or ineffective in later studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Scientia Clinical Reserch Ltd
RECRUITING

Sydney, New South Wales, 2031, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.